In analogy to molecular biomarkers that have been used for the identification of patients with targetable oncogenes [21], it has been assumed that tumor-infiltrating T lymphocytes (TILs) as predictive biomarker for clinical benefit to PD-1 blockade in patients with advanced NSCLC [22–24]. Here, PDCD1 is linked to neoplasm.